Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.57 |
| ▸ | MAPT | P10636 | 4/20 | 0.57 |
| ▸ | TSHR | P16473 | 3/20 | 0.57 |
| ▸ | TP53 | P04637 | 3/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | CCR3 | P51677 | 2/20 | 0.54 |
| ▸ | FAAH | O00519 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | PTGER3 | P43115 | 6/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4034536 | 0.80 | MCHR1 (0.65) | MAPTCCR3NPC1RAB9AALDH1A1 | |
| SCHEMBL5580108 | 0.79 | CCR3 (0.58) | KDM4EMAPTTSHRTP53HSD17B10 | |
| SCHEMBL3928596 | 0.79 | CCR3 (0.58) | KDM4EMAPTTSHRTP53HSD17B10 | |
| SCHEMBL6840044 | 0.79 | CCR3 (0.58) | KDM4EMAPTTSHRTP53HSD17B10 | |
| SCHEMBL5741334 | 0.77 | CCR3 (0.56) | KDM4EMAPTTSHRTP53HSD17B10 | |
| SCHEMBL5741336 | 0.77 | CCR3 (0.56) | KDM4EMAPTTSHRTP53HSD17B10 | |
| SCHEMBL5744159 | 0.77 | CCR3 (0.53) | KDM4EMAPTTSHRTP53HSD17B10 | |
| SCHEMBL5556626 | 0.76 | POLB (0.60) | KDM4EMAPTTSHRGAACCR3 | |
| SCHEMBL5562675 | 0.75 | MEN1 (0.61) | KDM4EMAPTGAAFAAHSMN1; SMN2 | |
| SCHEMBL4033889 | 0.75 | MCHR1 (0.58) | KDM4EMAPTTSHRTP53HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1453514-B1 | PIPERAZINE DERIVATIVES FOR USE AS CCR-3 RECEPTOR ANTAGONISTS IN THE TREATMENT OF ASTHMA | HOFFMANN LA ROCHE (CH) | 2007-07-18 | — | — | EP | claimed |
| US-6906073-B2 | Piperazine CCR-3 receptor antagonists | ROCHE PALO ALTO LLC (US) | 2005-06-14 | — | — | US | claimed |
| EP-1453514-A1 | PIPERAZINE DERIVATIVES FOR USE AS CCR-3 RECEPTOR ANTAGONISTS IN THE TREATMENT OF ASTHMA | F. HOFFMANN-LA ROCHE AG (CH) | 2004-09-08 | — | — | EP | claimed |
| US-20030176441-A1 | Piperazine CCR-3 receptor antagonists | ROCHE PALO ALTO LLC | 2003-09-18 | — | — | US | claimed |
| WO-2003045393-A1 | PIPERAZINE DERIVATIVES FOR USE AS CCR-3 RECEPTOR ANTAGONISTS IN THE TREATMENT OF ASTHMA | F. HOFFMANN-LA ROCHE AG (CH) | 2003-06-05 | — | — | WO | claimed |
| EP-1453514-B1 | PIPERAZINE DERIVATIVES FOR USE AS CCR-3 RECEPTOR ANTAGONISTS IN THE TREATMENT OF ASTHMA | HOFFMANN LA ROCHE (CH) | 2007-07-18 | — | — | EP | disclosed |
| US-6906073-B2 | Piperazine CCR-3 receptor antagonists | ROCHE PALO ALTO LLC (US) | 2005-06-14 | — | — | US | disclosed |
| EP-1453514-A1 | PIPERAZINE DERIVATIVES FOR USE AS CCR-3 RECEPTOR ANTAGONISTS IN THE TREATMENT OF ASTHMA | F. HOFFMANN-LA ROCHE AG (CH) | 2004-09-08 | — | — | EP | disclosed |
| US-20030176441-A1 | Piperazine CCR-3 receptor antagonists | ROCHE PALO ALTO LLC | 2003-09-18 | — | — | US | disclosed |
| WO-2003045393-A1 | PIPERAZINE DERIVATIVES FOR USE AS CCR-3 RECEPTOR ANTAGONISTS IN THE TREATMENT OF ASTHMA | F. HOFFMANN-LA ROCHE AG (CH) | 2003-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176441-A1 | Piperazine CCR-3 receptor antagonists | CCR3, CCR1, CCRL2 | KDM4E 2771/4885MAPT 4344/4885TSHR 858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.